Streetbeat News

AGIO

Agios Pharmaceuticals, Inc.

https://www.agios.com

Industry

Biotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Open

51.66

Mkt cap

3.1B

Volume

1.2M

High

55.17

P/E Ratio

4.53

52-wk high

55.17

Low

51.28

Div yield

N/A

52-wk low

20.40

Raymond James analyst Danielle Brill has reinstated an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) and set a price target of $51.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:54 pm

Agios Pharmaceuticals' stock is experiencing a decline following a downgrade by Leerink Partners from Outperform to Market Perform, along with a reduced price target from $60 to $56.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:16 pm

Several top Wall Street analysts have downgraded their ratings for notable companies, including Celldex Therapeutics, Bumble Inc., HP Inc., Agios Pharmaceuticals, and Udemy. These downgrades reflect changes in analyst sentiment and could impact stock prices.

Portfolio Pulse from Avi Kapoor

September 27, 2024 | 12:46 pm

Top Wall Street analysts have updated their price targets and ratings for several companies, including Travere Therapeutics, Rocket Lab USA, MP Materials, ESCO Technologies, Accenture, Jabil, Agios Pharmaceuticals, Wynn Resorts, Micron Technology, and Udemy. These changes reflect varying outlooks on the companies' future performance.

Portfolio Pulse from Avi Kapoor

September 27, 2024 | 12:04 pm

Leerink Partners has downgraded Agios Pharmaceuticals from Outperform to Market Perform and reduced its price target from $60 to $56.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 11:29 am

Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Agios Pharmaceuticals (NASDAQ:AGIO).

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 2:14 pm

RBC Capital analyst Gregory Renza has reiterated an Outperform rating for Agios Pharmaceuticals, maintaining a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:08 pm

The FDA has granted Orphan Drug Designation to Agios Pharmaceuticals' Tebapivat (AG-946) for the treatment of Myelodysplastic Syndromes. This designation is significant as it provides certain benefits to Agios, including market exclusivity and potential tax credits.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 11:01 am

Agios Pharmaceuticals shares are trading higher after the company announced it will receive $1.1 billion in milestone payments.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:52 pm

Agios Pharmaceuticals is set to receive $1.1 billion in milestone payments following the FDA approval of Vorasidenib. The payments include $905 million from Royalty Pharma and $200 million from Servier, expected in Q3 2024. This will boost Agios' pro-forma cash position to $1.7 billion as of June 30, 2024, enabling the company to prepare for potential launches of PYRUKYND® (Mitapivat) in Thalassemia in 2025 and Sickle Cell Disease in 2026, and to drive pipeline progress.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.